company background image
NBSE logo

NeuBase Therapeutics NasdaqCM:NBSE Stock Report

Last Price

US$0.71

Market Cap

US$2.7m

7D

3.1%

1Y

-84.5%

Updated

25 Feb, 2024

Data

Company Financials

NeuBase Therapeutics, Inc.

NasdaqCM:NBSE Stock Report

Market Cap: US$2.7m

NBSE Stock Overview

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.

NBSE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NeuBase Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeuBase Therapeutics
Historical stock prices
Current Share PriceUS$0.71
52 Week HighUS$5.40
52 Week LowUS$0.59
Beta0.95
1 Month Change12.96%
3 Month Change9.23%
1 Year Change-84.47%
3 Year Change-99.62%
5 Year Changen/a
Change since IPO-99.22%

Recent News & Updates

Recent updates

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

Aug 26
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

Aug 11

NeuBase Therapeutics promotes Dr. William Mann to President and COO

Jun 29

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12
We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23
Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19
We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15
Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Shareholder Returns

NBSEUS BiotechsUS Market
7D3.1%1.5%1.3%
1Y-84.5%10.5%25.6%

Return vs Industry: NBSE underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: NBSE underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is NBSE's price volatile compared to industry and market?
NBSE volatility
NBSE Average Weekly Movement19.8%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: NBSE's share price has been volatile over the past 3 months.

Volatility Over Time: NBSE's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a37Todd Branninghttps://www.neubasetherapeutics.com

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene.

NeuBase Therapeutics, Inc. Fundamentals Summary

How do NeuBase Therapeutics's earnings and revenue compare to its market cap?
NBSE fundamental statistics
Market capUS$2.66m
Earnings (TTM)-US$24.59m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NBSE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$24.59m
Earnings-US$24.59m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.59
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NBSE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.